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The insulin-linked polymorphic region (ILPR) of the human insulin gene promoter region
forms G-quadruplex structures in vitro. Previous studies show that insulin and insulin-like
growth factor-2 (IGF-2) exhibit high affinity binding in vitro to 2-repeat sequences of ILPR
variants a and h, but negligible binding to variant i. Two-repeat sequences of variants a and h
form intramolecular G-quadruplex structures that are not evidenced for variant i. Here we
report on the use of protein digestion combined with affinity capture and MALDI-MS
detection to pinpoint ILPR binding sites in insulin and IGF-2. Peptides captured by ILPR
variants a and h were sequenced by MALDI-MS/MS, LC-MS and in silico digestion. On-bead
digestion of insulin-ILPR variant a complexes supported the conclusions. The results indicate
that the sequence VCG(N)RGF is generally present in the captured peptides and is likely
involved in the affinity binding interactions of the proteins with the ILPR G-quadruplexes. The
significance of arginine in the interactions was studied by comparing the affinities of
synthesized peptides VCGERGF and VCGEAGF with ILPR variant a. Peptides from other
regions of the proteins that are connected through disulfide linkages were also detected in
some capture experiments. Identification of binding sites could facilitate design of DNA
binding ligands for capture and detection of insulin and IGF-2. The interactions may have
biological significance as well. (J Am Soc Mass Spectrom 2009, 20, 1974–1982) © 2009
American Society for Mass SpectrometryThe insulin-linked polymorphic region (ILPR) islocated in the promoter region of the humaninsulin gene, which is adjacent to the IGF-2 gene.
The ILPR contains tandem repeats of closely related,
G-rich sequences that are 14–15 bases long [1–19]. A
dozen or so ILPR variant sequences have been identi-
fied, the most common of which is variant a (5=-
ACAG4TGTG4-3=). Oligonucleotides containing two or
more repeats of some variants, including variants a and h,
have been shown to form intramolecular G-quadruplex
structures in vitro [4–8]. The ILPR has been the subject of
numerous studies linking it to regulation of the insulin
and IGF-2 genes and type 1 diabetes susceptibility
[9–19].
We previously reported that insulin exhibits high af-
finity binding in vitro through its -chain to the intramo-
lecular G-quadruplex formed by a 2-repeat variant a
oligonucleotide [20]. We subsequently observed that
IGF-2 also exhibits high affinity binding to this oligonu-
cleotide and investigated the affinity binding interactions
of insulin and IGF-2 with oligonucleotides comprising
2-repeat sequences of ILPR variants a, h, and i (ILPRa,
ILPRh, and ILPRi, respectively) using affinity matrix
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(affinity MALDI-MS) and surface plasmon resonance
(SPR) [7].
In the present work, we used two different methods
to determine the location of the binding site in insulin
and IGF-2 for the G-quadruplexes formed by ILPRa and
ILPRh. Both methods employed affinity capture of
peptides produced by enzymatic digestion of insulin
and IGF-2 or of synthetic peptides. In one method, the
ILPR oligonucleotides were covalently immobilized on
fused silica MALDI probe surfaces as previously de-
scribed [21, 22], and captured peptides were analyzed
directly on the surface using MALDI-TOF-MS. In the
second method, biotinylated ILPR oligonucleotides were
incubated with the protein digests or synthetic peptides,
followed by capture of the oligonucleotides and any
associated peptides on streptavidin-coated beads. Ad-
ditionally, insulin and IGF-2 complexes with ILPRa
were captured on the beads followed by on-bead diges-
tion and MALDI-MS analysis of the peptides remaining
in the captured complexes. In both bead experiments,
the captured peptides were eluted from the beads and
sequenced using both MALDI-TOF/TOF-MS/MS and
in silico digestion of insulin and IGF-2. The importance
of arginine in the binding interaction was probed by
using synthetic peptides in which the arginine was
replaced by alanine.
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Materials
PBS buffer (phosphate buffer-saline, 10 mM potassium
phosphate buffer, 150 mM potassium chloride, pH 7.32),
solvents, -cyano-4-hydroxycinnamic acid (CHCA), 6-aza-
2-thiothymine (ATT), ammonium hydrogen carbonate
and dithiothreitol (DTT) were from Sigma (St. Louis,
MO, USA). Recombinant human proteins including
insulin, IGF-2, and chymase were from Sigma. Peptides
VCGERGF and VCGEAGF (referred to hereinafter as
Peptide R and Peptide A, respectively) were synthe-
sized by 21st Century Biochemicals (Marlboro, MA,
USA). Oligonucleotides that were either thiol-modified
or biotinylated at the 5=-end were synthesized by Euro-
gentec (San Diego, CA, USA). The oligonucleotides
included ILPRa (5=-(ACAGGGGTGTGGGG)2-3=), ILPRh
(5=-(ACAGGGGTGTGGGC)2-3=), and ILPRi (5=-(ACA-
GGGTCCTGGGG)2-3=). Streptavidinated magnetic beads
(M-280 Dyna beads) were from Invitrogen (Oslo, Norway).
Chymase Digestion of Insulin and IGF-2
Insulin and IGF-2 solutions (10 M in PBS buffer for
affinity MALDI MS, LC-MS, and 5 M in PBS buffer for
the affinity bead capture) were incubated with chymase
(0.37 M) at 37 °C for 30 min. The chymase cleavage
sites in insulin and IGF-2 are shown in Figure 1. The
preferential cleavage order is: Phe (F)-|-Xaa  Tyr
(Y)-|-Xaa  Trp (W)-|-Xaa  Leu (L)-|-Xaa (where X is
any amino acid) [23].
Peptide Capture and Analysis on ILPR
Oligonucleotide-Modified MALDI Probes
The 5=-thiol modified DNA oligonucleotides were co-
valently attached to fused silica MALDI probe chips (20
mm  20 mm  0.75 mm; Valley Design, Westford,
Figure 1. Peptide sequences of insulin and IGF-2. Chymase
cleavage sites are indicated in red and cleavage occurs on the
C-terminus side of the site. Cysteines crosslinked with disulfide
bonds are in blue.MA, USA) through a covalent linker as previously
described [7, 20–22]. Immediately before surface attach-
ment, oligonucleotides were heated to 95 °C for 5 min to
melt any intermolecular and intramolecular structures
and then cooled to room temperature in the presence of
K ion [7].
For peptide capture, unless otherwise noted, 1 L of
peptide sample was incubated on each oligonucleotide-
coated spot at room temperature for 30 min. Chips were
then rinsed with deionized water for 30 s to remove any
weakly bound or unbound peptides and dried under
nitrogen gas. This incubation-rinse cycle was repeated
two more times, each with a new 1 L aliquot of
sample, to concentrate captured peptide at the surface.
MALDI matrix (a mixture of equal parts saturated
CHCA solution containing 0.3% trifluoroacetic acid and
water) was then applied to the spot and allowed to
crystallize. The chip was then mounted on a custom
aluminum MALDI target and each spot was analyzed
by MALDI-TOF-MS using a Bruker AutoFlex II instru-
ment (Billerica, MA, USA). After use, the spots were
rinsed with 50% acetonitrile in water to remove the
MALDI matrix, peptides and any concomitants. PBS
buffer was applied to the surface to reconstitute it
before reuse. Surfaces were periodically tested for sam-
ple carryover, contamination and degradation of the
oligonucleotide-modified surface by MALDI-MS in the
absence of applied sample. In no case was any car-
ryover, contamination, or degradation indicated.
Peptide Capture on Streptavidinated Beads and
MS Analysis of Captured Peptides
For the affinity bead experiments, the peptides first
were incubated with the 5=-biotinylated DNA oligonu-
cleotides in solution. The solutions were then incubated
with the streptavidinated beads to capture the biotinyl-
ated oligonucleotides and their associated peptides. As
described above for the affinity MALDI-MS experi-
ments, before use the oligonucleotides were heated and
then cooled in the presence of K to promote intramo-
lecular G-quadruplex formation.
After digestion of insulin or IGF-2 by chymase,
biotinylated ILPRa or ILPRh was incubated with the
protein digest solution (concentration ratio 1:1 DNA:
intact protein) at room temperature for 30 min in a
shaker. The solution was then transferred to a solution
of the streptavidinated beads (10 mg/mL) and incu-
bated at room temperature for 30 min in a shaker [24].
The solution contained 200 pmol of biotinylated ILPR
variant per mg bead. The beads were then rinsed with
PBS buffer to remove weakly associated and unbound
peptides and sample concomitants. Captured peptides
were then eluted from the oligonucleotides by incubat-
ing with 5% formic acid solution for 10 min at room
temperature in a shaker. The supernatant in formic acid
was mixed with the CHCA MALDI matrix at 1:1
volume ratio. One L of this mixture was applied to an
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analyzed by MALDI-TOF-MS. The same procedure was
used for the affinity capture studies of the synthesized
peptides R and A, except that instead of protein digest,
the incubation solution contained 5 M Peptide R
and/or Peptide A and 5 M biotinylated ILPRa.
For the complex formation studies of peptides A and
R with ILPRa, a mixture of 50 M each of biotinylated
ILPRa and Peptide R or A was incubated at RT in a
shaker for 30 min. A 1 L aliquot of the mixture was
applied onto the aluminum MALDI probe and 1 L of
MALDI matrix (saturated ATT solution with 10 mM
NH4HCO3 dissolved in ACN) was then applied. The
MALDI probe was mounted and each spot analyzed by
MALDI-TOF-MS using a Bruker AutoFlex II instrument
(Billerica, MA) in negative ion detection mode.
For studies of intact protein complexation with ILPRa
followed by on-bead digestion of the proteins in the
captured complexes, insulin or IGF-2 was first incubated
with the 5=-biotinylated ILPRa in solution (concentration
ratio 1:1 DNA:intact protein) at RT for 30 min in a shaker.
The solution was then mixed with a solution of the
streptavidinated beads (10 mg/mL) and incubated at RT
for 30 min in a shaker [24]. After that, chymase was added
to the beads to digest the captured insulin or IGF-2 at
37 °C for 30 min. The beads were then rinsed with PBS
buffer to remove weakly associated and unbound pep-
tides and sample concomitants, and the remaining cap-
tured peptideswere released from the beads and analyzed
by MALDI-TOF-MS as described above.
MS/MS Analysis of Peptides by MALDI-TOF/
TOF-MS/MS, LC-MS/MS and In Silico Digestion
For MALDI-TOF/TOF-MS/MS analysis, equal volumes
of protein digest and the CHCA MALDI matrix were
mixed and 1–1.5 L of the mixture was applied to the
aluminum MALDI probe, allowed to crystallize, and
analyzed using LIFT detection and positive modes. The
following were the high voltage settings for post source
decay (PSD): ion source 1, 8 kV; ion source 2, 7.2 kV;
lens, 3.6 kV; reflector, 13.86 kV; LIFT 1, 19 kV; LIFT 2,
3.1 kV.
The sample was analyzed by MALDI-TOF/TOF-
MS/MS using a Bruker UltraFlex III instrument (Billerica,
MA). In silico digestion was performed using online
software “Protein Prospector” from the website of Univer-
sity of California, San Francisco, with the following search
parameters: database, user protein; digest, chymotrypsin;
variable modification, none; minimum peptide length, 3;
maximum missed cleavages, 5. Chymotrypsin was used
since chymase digestion is not available for the in silico
digestion. Chymase and chymotrypsin cleave insulin and
IGF-2 at the same amino acids and so the substitution is
valid.
For peptide sequencing by LC-MS/MS, 5 L protein
digest was loaded into the Agilent Zorbax SB-C18
capillary column (particle size, 5 m; i.d., 0.52 mm;length, 150 mm) by Agilent 1200 Series nano-flow LC
system (Palo Alto, CA, USA), with flow rate of 30
L/min at 4 °C. The elution time was set to 40 min,
including 25 min for gradient elution, starting at 5%
ACN in 0.5% formic acid aqueous solution and ending
at 80% ACN, followed by a washing column with 80%
ACN for 5 min and then 10 min to return the mobile
phase back to 5% ACN. Peptides were ionized under
ESI mode and detected by a LTQ-Orbitrap instrument
(Thermo Scientific, Waltham, MA, USA). Two scan
events were set up for insulin and IGF-2 peptide
fragmentation under MS2 and MS3 scan mode. Settings
for the first scan event were: FTMS analyzer, normal
mass range; resolution, 60,000; scan type, full; polarity,
positive; MS/MS on 677.62 (3) for insulin peptide and
665.97 (3) for IGF-2 peptide; CID, 36 eV. Settings for
the second scan event were: FTMS analyzer, normal
mass range; resolution, 30,000; data dependent scan for
MS/MS, most intense ion selected from first scan event;
CID, 35 eV; minimum signal required, 1000.
Results
Insulin and IGF-2 Peptide Complexes with
Biotinylated ILPR Oligonucleotides Captured on
Streptavidinated Beads
Figure 2 (top) shows the MALDI-TOF spectrum of
insulin digest peptides released from the ILPRa com-
plexes after capture on the streptavidinated beads.
Figure 2 (bottom) shows the MALDI-TOF mass spec-
trum of the total insulin peptide digest. For ILPRa, there
is significant capture of an insulin peptide at m/z 1027
and indication of capture of a peak atm/z 880 as well. By
comparing results of in silico digestion of insulin and
peptide sequencing of the peaks in Figure 2 (top) using
MALDI-TOF/TOF analysis of m/z 1027 (Supplementary
Figure 2. MALDI-MS of insulin peptides eluted from biotinyl-
ated ILPRa (top) after capture of the oligonucleotides and associ-
ated peptides on streptavidinated beads and total insulin peptide
digest profile (bottom).
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of this article), and m/z 880 (not shown), we obtained
the sequences LVCGERGFF and LVCGERGF, respec-
tively. While the evidence for m/z 880 has relatively
high uncertainty, its sequence is consistent with chy-
mase cleavage to remove the Phe (F) at the C-terminus
of the peptide corresponding to the peak at m/z 1027,
and so its presence or absence does not change the
overall conclusions regarding binding sequences.
For ILPRh, the spectrum of insulin peptides released
from the complexes after capture on the streptavidi-
nated beads [Figure 3a (top)] showed only one peak, at
m/z 2030. Based on results of in silico digestion of
Figure 3. (A) MALDI-MS of insulin peptide
(bottom) after capture of the oligonucleotides an
MALDI-TOF/TOF-MS/MS of insulin peptide at m/zinsulin, there is no peptide corresponding to m/z 2030;
however, the Peptide Sequence Editor indicates that it
could correspond to peptides GIVEQCCTSICSLY (m/z
1518) and CGSHL (m/z 515) cross-linked by the disul-
fide bond formed between the second cysteine of
GIVEQCCTSICSLY and the cysteine of CGSHL. This is
supported by the spectra of the insulin digest without
and with DTT treatment to destroy the disulfide bonds
(Supplementary Figure S2), which show the disappear-
ance of the peak at m/z 2030 after DTT treatment.
Further support is provided by the MALDI-TOF/TOF
spectrum of the peak at m/z 2030 (Figure 3b) and by the
LC-MS/MS spectrum (Supplementary Figure S3).
ted from biotinylated ILPRh (top) and ILPRi
ociated peptides on streptavidinated beads. (B)s elu
d ass2030 and the results of peptide sequencing.
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incubation with ILPRi and capture on the streptavidi-
nated beads [Figure 3a (bottom)], indicating the absence
of complex formation between ILPRi and insulin pep-
tides. This is consistent with previous work that
showed no evidence of affinity interaction between
intact insulin protein and ILPRi, which does not form
the G-quadruplex structure evidence for ILPRa and
ILPRh in the CD spectra [7].
Figure 4a (top) shows the MALDI-MS spectra of
IFG-2 digest peptides released from the ILPRa com-
plexes after capture on the streptavidinated beads.
Figure 4a (bottom) shows the MALDI-TOF mass spec-
Figure 4. (A) MALDI-MS of IGF-2 peptides elu
oligonucleotides and associated peptides on str
profile (bottom). (B) MALDI-TOF/TOF-MS/MS
sequencing.trum of the IGF-2 peptide digest. For IGF-2 with ILPRa,
there are peaks at m/z 1191, m/z 1649 and m/z 1994. By
comparing results of in silico digestion of IGF-2 and
peptide sequencing using MS/MS analysis of m/z 1191
(Supplementary Figure S4), we obtained the sequences
QFVCGDRGFY. Based on the results of in silico diges-
tion of IGF-2, there are no peptides corresponding to
either m/z 1649 or m/z 1995. We therefore looked further
into the structure of IGF-2 and considered the possibil-
ity that the disulfide bonds could contribute to the
peptide mass. The addition of a sulfur atom to the
peptide with m/z 1617 with sequence VDTLQFVCGDRGFY
would account for the peak at m/z 1649. The peak at m/z
om biotinylated ILPRa (top) after capture of the
idinated beads and total IGF-2 peptide digest
F-2 peptide at m/z 1994 and results of peptideted fr
eptav
of IG
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(m/z 1191) and CATPAKSE (m/z 805) with two cysteines
cross-linked by disulfide bonds, as indicated by the
Peptide Sequence Editor. DTT treatment of the IGF-2
digest to destroy disulfide bonds showed that DTT
caused the disappearance of the peaks at m/z 1649 and
1995 (Supplementary Figure S5), which is consistent
with the presence of disulfide bonds in the captured
peptides corresponding to these peaks. Further support
is provided by the MALDI-TOF/TOF spectrum (Figure
4b) and the LC-MS/MS spectrum (Supplementary Fig-
ure S8) of the peak at m/z 1994. MALDI-MS/MS anal-
ysis of the peak at m/z 1649 supports the presence of
disulfide bond (Supplementary Figure S7) in the pro-
posed structure. For IGF-2 with ILPRh, there is only the
single peak at m/z 1995 (Supplementary Figure S8, top).
As was the case for insulin, no peaks are evident in
the spectrum for ILPRi (Supplementary Figure S8,
bottom), again consistent with the previously re-
ported absence of affinity interactions between intact
IGF-2 and ILPRi [7].
Affinity Capture of Insulin and IGF-2 Peptides on
ILPR-Modified MALDI Probe Surfaces
Results for capture of insulin digest peptides on
ILPR-modified MALDI probe surfaces are shown
in Supplementary Figure S9. For ILPRa (Supplemen-
tary Figure S9, top) there is only one peak, at m/z
3414, which may correspond to the insulin -chain
(FVNQHLCGSHLVEALYLVCGERGFFYTPKT, MW 3431)
with the loss of 17 mass units. Previous work has shown
that insulin binds to ILPRa through the -chain [20] and
possibly any remaining -chain after digestion prefer-
entially binds to the surface-immobilized ILPRa. For
ILPRh (Supplementary Figure S9, bottom), there is a
single peak at m/z 880, which was also suggested for
ILPRa complexation with insulin peptides (Figure 2,
top) and corresponds to sequence LVCGERGF. No
peaks were observed for ILPRi (not shown).
Results for capture of IGF-2 digest peptides on
ILPR-modified MALDI probe surfaces are shown in
Supplementary Figure S10. For ILPRa (Supplementary
Figure S10, top), there are peaks at m/z 1191 and 1617.
Based on the results of in silico digestion and peptide
sequencing already discussed for the affinity bead
studies, m/z 1191 corresponds to QFVCGDRGFY and
m/z 1617 corresponds to VDTLQFVCGDRGFY; both
of these peptides contain the common sequence of
VCG(N)RGF. For ILPRh (Supplementary Figure S10, bot-
tom) there is the peak at m/z 1191 corresponding to
QFVCGDRGFY as well as peaks at m/z 1163 and 1396.
Results of in silico digestion indicate peptides with se-
quences of RPSETLCGGEL and AYRPSETLCGGEL, re-
spectively. No further sequencingwas performed on these
peaks, which were also captured on ILPRi spots (not
shown) and likely associate through different bindingmechanisms, possibly nonspecific, that do not involve the
intramolecular G-quadruplex of ILPRa and ILPRh.
On-Bead Capture and Digestion of Intact Insulin
and IGF-2 Complexed with Biotinylated ILPRa
To compare capture of protein digest peptides dis-
cussed above with capture of intact proteins followed
by digestion, insulin and IGF-2 were incubated with
biotinylated ILPRa, followed by capture of the ILPRa
and ILPRa-protein complexes on the streptavidinated
beads. The captured proteins were then subjected to
chymase digestion directly on the beads. The free
peptides were then removed by washing and the re-
maining peptides still associated with the ILPRa were
released and analyzed by MALDI-TOF. The results
(Supplementary Figure S11) indicate a peptide with m/z
3348 for insulin and a peptide with m/z 1191 for IGF-2.
Although there was insufficient protein recovered in
these experiments for further sequencing, the insulin
peptide most likely corresponds to a large portion of the
-chain and is consistent with the capture of a slightly
larger peptide (m/z 3414) at the ILPRa-modified MALDI
probe surface (Supplementary Figure S9, top). The IGF-2
peptide corresponds to the sequence QFVCGDRGFY that
was detected in the other capture experiments as well.
These experiments support the involvement of the com-
Figure 5. (A) Relative affinity MALDI-MS capture and detection
of peptide R and peptide A on ILPRa-modified surface. (B)
Complex formation between peptide R (top) and peptide A
(bottom) and ILPRa determined in negative ion mode for
MALDI-MS detection of ILPRa and its peptide complexes.
ed cy
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ILPRa with both proteins and also confirms the strong
association of the insulin -chain with ILPRa.
Importance of Arginine in the Binding Interactions
It has been reported that arginine plays a role in
interactions between proteins and G-quadruplex DNA
structures [25]. Since the insulin and IGF-2 peptides
captured on the ILPR G-quadruplexes in this work
contain arginine in the common sequences, we com-
pared binding of the peptide VCGERGF (“Peptide R”)
and VCGEAGF (“Peptide A”) in which the arginine is
replaced by alanine. The results are shown in Figure 5a
for capture of the two peptides by biotinylated ILPRa
using the affinity bead procedure. Capture is greater for
Peptide R compared with Peptide A. We also studied
complex formation between ILPRa and the two pep-
tides in solution using MALDI-MS in negative ioniza-
tion mode to detect the DNA and its complexes. The
results (Figure 5b) indicate that only R forms a complex
with ILPRa, supporting the importance of arginine in
the binding interaction. To determine whether the effect
is due to direct interactions between arginine and the
ILPR G-quadruplex or to the effects of arginine on the
overall conformation of the peptide, we collected CD
spectra of the two peptides. The results (not shown)
indicate that there is no significant conformational
difference between the peptides, suggesting that argi-
nine is directly involved in the interaction with the
oligonucleotides. This does not mean that conformation
Table 1. Results for affinity bead capture of insulin and IGF-2 p
ILPR Olig
ILPR a
Insulin peptides m/z 880: LVCGERGF
m/z 1027: LVCGERG
IGF-2 peptides †m/z 1191: QFVCGD
m/z 1650: VDTLQFVC
*m/z 1995: QFVCGD
|
CATPAKS
*Indictates two strands connected by disulfide linkage between italiciz
†Also recovered from on-bead digestion.
Table 2. Results for affinity capture of insulin and IGF-2 peptid
ILPR Olig
ILPR a
Insulin peptides m/z 3414: FVNQHLCGSHLVEALYLVCGE
IGF-2 peptides m/z 1191: QFVCGDRGFY
m/z 1617: VDTLQFVCGDRGFYdoes not play a role in the binding of the intact proteins
or their peptides with the G-quadruplexes; rather, it
indicates the likelihood that the conformation of the
protein or peptide facilitates contact between arginine
and the G-quadruplex.
Discussion
Tables 1 and 2 summarize the peptide sequences that
correspond to the peaks in the various capture experi-
ments. The sequence VCG(N)RGF is common to all of
the insulin and IGF-2 peptides captured by ILPRa. It is
present in some but not all of the peptides captured by
ILPRh. IGF-2 with ILPRh also shows nonspecific capture
of peptides that are also captured by ILPRi. We conclude
from these results that the sequence VCG(N)RGF plays a
key role in the affinity binding of insulin and IGF-2
proteins with the G-quadruplexes formed by ILPRa and
ILPRh, and that the specificity is greater for ILPRa than
ILPRh. Figure 6 shows the location of the common pep-
tide in the protein structures. The sequence is contained in
the insulin -chain, and previous work has shown that the
affinity interactions between insulin and ILPRa occur
through the -chain [20]. The results indicate the direct
participation of the arginine in the common peptide in the
affinity binding interactions.
It is interesting to consider the effects of ILPR immo-
bilization and pre-capture protein digestion versus
post-capture protein digestion on the results. For insu-
lin with ILPRh and IGF-2 with both ILPRa and ILPRh,
the main difference between complexation in solution
e complexes with ILPR oligonucleotides
cleotide
ILPR h
*m/z 2030:
GIVEQCCTSICSLY (-chain)
|
CGSHL (-chain)
*m/z 1995: QFVCGDRGFY
GFYS |
CATPAKSE
steines (C).
ILPR-modified surfaces in affinity MALDI-TOF-MS
cleotide
ILPR h
FYTPKT-NH2 m/z 880: LVCGERGF
m/z 1191: QFVCGDRGFY
*m/z 1163: RPSETLCGGEL
*m/z 1396: YRPSETLCGGELeptid
onu
FF
RGFY
GDR
RGFY
Ees by
onu
RGF(*not sequenced, also captured by ILPRi)
www
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disulfide linkages in some of the peptides detected in
the solution complexes but not in the peptides captured
on the immobilized ILPR. A likely explanation is that
immobilized ILPR will be constrained both in terms of
possible conformations as well as modes of interaction
with the peptides compared to free ILPR in solution. It
should be noted that the constrained model is a more
accurate model for the chromosomal ILPR and may
therefore be a better predictor of possible interaction in
live cells. Interestingly, in the case of insulin with
ILPRa, almost the entire -chain is captured when (1)
the ILPRa is incubated with intact insulin before diges-
tion and apparently protected from digestion, and (2)
when insulin peptides are captured by immobilized
ILPRa at the MALDI probe surface. This anomalous
behavior is consistent with previous work indicating at
least two interaction modes between insulin and ILPRa,
one with a KD about 10
7 M and the other with a KD
about pM, while insulin with ILPRh and IGF-2 with
both ILPRa and ILPRh have single interaction modes
with KDs about 10
8 to 109 M [7]. Further studies are
underway to model the binding interactions, including
the effects of constraints due to DNA immobilization,
and explore other variants of the ILPR sequence.
Conclusion
Knowledge of the affinity binding site in insulin and
IGF-2 for G-quadruplexes formed by the ILPR oligonu-
cleotides offers new insight into these interactions that
Figure 6. Location of common sequence VCG
Other possible binding sites are in bold and red.
in the RCSB Protein Data Bank website (http://could be used to design affinity reagents as well asincreasing our understanding of the specificity of
G-quadruplex-protein interactions. The binding interac-
tions of the insulin and IGF-2 proteins or peptides with
the ILPR G-quadruplexes may have biological signifi-
cance, for example in regulation of the insulin and
IGF-2 genes, and warrant further study.
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